Regulation of Human PAX6 Expression by miR-7

Maria Needhamsen1,2, Robert B. White1,2,4, Keith M. Giles3, Sarah A. Dunlop2 and Meghan G. Thomas1,2

1Parkinson’s Centre (ParkC), School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia. 2Experimental and Regenerative Neurosciences (EaRN), School of Animal Biology, University of Western Australia, Crawley, Western Australia, Australia. 3Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia. 4School of Anatomy, Physiology and Human Biology, University of Western Australia, Crawley, Western Australia, Australia.

ABSTRACT: The paired box gene 6 (PAX6) is a powerful mediator of eye and brain organogenesis whose spatiotemporal expression is exquisitely controlled by multiple mechanisms, including post-transcriptional regulation by microRNAs (miRNAs). In the present study, we use bioinformatic predictions to identify three candidate microRNA-7 (miR-7) target sites in the human PAX6 3′ untranslated region (3′-UTR) and demonstrate that two of them are functionally active in a human cell line. Furthermore, transient transfection of cells with synthetic miR-7 inhibits PAX6 protein expression but does not alter levels of PAX6 mRNA, suggesting that miR-7 induces translational repression of PAX6. Finally, a comparison of PAX6 3′-UTRs across species reveals that one of the functional miR-7 target sites is conserved, whereas the second functional target site is found only in primates. Thus, the interaction between PAX6 and miR-7 appears to be highly conserved; however, the precise number of sites through which this interaction occurs may have expanded throughout evolution.

KEYWORDS: miR-7, PAX6, miRNA, 3′-UTR

Introduction

MicroRNA (miRNA) regulation of protein expression adds a subtle layer of complex fine-tuning on top of numerous modes of protein production and destruction. miRNAs typically bind to specific sites within the 3′ untranslated regions (3′-UTRs) of their target mRNAs, to impart post-transcriptional silencing, either through translational repression and/or mRNA decay.1,2 In animals, miRNAs typically exhibit partial complementary base pairing to their mRNA targets, with the “seed region” of six to eight nucleotides toward the 5′end of the miRNA being important for target specificity.3 miRNA target efficacy is predicted to increase with the number of Watson-Crick matches to the seed region and is also dependent on base composition at nucleotide position 1.2,4 For example, a perfect match to nucleotides 2-8, referred to as a “7Mer-m8” target site, has a higher hierarchy rating compared to a “7Mer-A1” target site, which only confers Watson-Crick base pairing to nucleotides 2-7.3 Noticeably, the latter has an A at nucleotide position 1, which again rates it higher than a “6Mer” with the same 2-7 seed match, but a different number 1 nucleotide (C, G, or T).4 However, other factors such as AU-rich neighbor nucleotides and accessibility may also influence site-efficacy.5,6 Hence, miRNAs target specific genes for post-transcriptional regulation, fine-tuning protein expression levels during critical processes such as cell proliferation, differentiation, and maturation.7

The functional roles of microRNA-7 (miR-7) have been extensively studied, as it is highly conserved, being detected in 81 species (October 2013: http://www.mirbase.org),8–10 and controls multiple cell signaling networks, including...
epidermal growth factor receptor,\textsuperscript{11} insulin-like growth factor,\textsuperscript{12} Hedgehog,\textsuperscript{13} and the mammalian target of rapamycin (mTOR) signaling pathways.\textsuperscript{14} miR-7 is also a critical regulator of multiple regulatory genes, including paired box gene 6 (\textit{PAX6}) in mice.\textsuperscript{5-9} \textit{PAX6} encodes a neurogenic transcription factor, which is highly conserved, both structurally and functionally, and is critical for neural tube polarization, brain regionalization, and eye formation.\textsuperscript{15-17} \textit{PAX6} is widely co-expressed with miR-7 in several tissues including the forebrain, pancreas, and retina where it is involved in regulating cellular differentiation.\textsuperscript{8-10}

Given the functional importance of the miR-7/\textit{PAX6} regulatory apparatus in controlling cell fate in mouse, we sought to evaluate whether this mechanism was conserved in humans. Herein we use bioinformatics to predict three miR-7 target sites in the human \textit{PAX6} 3'-UTR and reporter gene assays to confirm the functional capacity of two of these predicted target sites. Further, we compare the human \textit{PAX6} 3'-UTR region across species and identify a conserved miR-7 3'-UTR target site present in many species, as well as a second functional miR-7 target site in the human \textit{PAX6} 3'-UTR that is specific to primates.

\textbf{Materials and Methods}

\textbf{Prediction of miR-7 target sites.} 3'-UTRs were identified using the “Spidey” freeware, which is part of the NCBI toolkit (http://www.ncbi.nlm.nih.gov/spidey/). Target sites for hsa-miR-7 within human \textit{PAX6} 3'-UTR (GenBank accession number: NM_001127612) were predicted using TargetScan software (release 6.2)\textsuperscript{8} with the following search criteria: species: human, human Entrez gene symbol: \textit{PAX6}, and miRNA name: hsa-miR-7. Target sites for miR-7 in 3'-UTRs of other species (GenBank accession numbers given in Supplementary Table 1) were predicted using a “Find in This Sequence” function available at GenBank to search for the miR-7 seed region (5'-GUCUUC-3'). Notably, only species that encode miR-7 (mirbase.org) are included in the analysis. Nucleotide position numbers for 3'-UTRs are listed in Supplementary Table 1.

\textbf{Luciferase reporter constructs.} Luciferase reporter plasmids were generated by ligating annealed DNA oligonucleotides containing each of the three predicted \textit{PAX6} 3'-UTR hsa-miR-7 7mer targets sites (NM_001127612.1; m8#1: nt. 2389–2441, m8#2: nt. 3613–3664, and A1#3: nt. 4170–4216) to the pMiR-REPORT luciferase plasmid (Ambion) via HindIII and SpeI restriction sites. Mutated (Mut) miR-7 seed target sites with three nucleotide substitutions were generated following the same procedure (for sequences refer to Supplementary Table 2). A perfect hsa-miR-7 target site (forward: 5'-CAACAAAAAT-CACAGTCCTTCTACA-3' and reverse: 5'-TGGAAGAGC-TAGTTATTTTGG-3') inserted in the pG3-control (Promega) firefly luciferase reporter vector was used as a control as previously described.\textsuperscript{11,18} Sequences of all plasmids were confirmed by Sanger DNA sequencing.

\textbf{Cell culture.} HeLa and HEK293 cells were obtained from the American Type Culture Collection (ATCC) and maintained at 37 °C and 5% CO\textsubscript{2} in Dulbecco’s modified Eagle’s medium (DMEM)/F-12-GlutaMAX (Life Technologies) supplemented with 5% fetal bovine serum (Serana) and 100 units/mL of Penicillin/Streptomycin (Life Technologies).

\textbf{Luciferase assays.} HEK293 cells in 24-well plates were co-transfected with 1) firefly luciferase reporter plasmid DNA (100 ng) containing either \textit{PAX6} 3'-UTR WT or Mut miR-7 target sites (7mer-m8#1, 7mer-m8#2, and 7mer-A1#3), 2) a control pRL-CMV \textit{Renilla} luciferase reporter plasmid (5 ng), and 3) precursor miRNAs (30 nM) purchased from Ambion, corresponding to human miR-7 (ID: PM10047) or a miRNA negative control (miR-NC) (ID: AM17110) using Lipofectamine 2000 (Invitrogen). Cells were harvested 24 hours post-transfection and assayed using a Dual-Luciferase Reporter Assay System (Promega) and an EnSpire Multimode Plate Reader (PerkinElmer). For data analysis, firefly luciferase activity was firstly normalized to \textit{Renilla} (transfection control) and then hsa-miR-7 was normalized to miR-NC transfected cells.

\textbf{Transfection.} HeLa cells were seeded 24 hours before transfection with miR-7 or miR-NC miRNA precursor molecules (30 nM) using RNAiMAX transfection reagent (Invitrogen). Cells were harvested at 24 hours (for RNA) or 72 hours (for protein) post-transfection.

\textbf{Western blotting.} HeLa cells were lysed by sonication (4 × 5 seconds) in ice-cold lysis buffer (0.1% SDS, 10 mM Tris–HCl pH 7.5) containing 1× complete inhibitor cocktail tablet (Roche) and protein concentrations determined by Bradford assay (Bio-Rad). Samples (70 µg) were electrophoretically separated on a 12.5% polyacrylamide gel, transferred to a Hybond-P membrane (Amersham Biosciences), and probed with anti-PAX6 (1:1,000; Abcam Clone AD2.38) or anti-β-actin (1:10,000; Sigma-Aldrich Clone AC-15) mouse monoclonal antibodies before detection with the commercially available Qlot 625 system (Molecular Probes) and UV light using Universal HooD II (Bio-Rad) for visualization of a representative image. A colored ladder was used to determine protein size (Marker Precision Plus Protein Kaleidoscope standard; Bio-Rad).

\textbf{RT-qPCR.} Total RNA was extracted (SV Total RNA Isolation System; Promega), quality assessed, and quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific) with threshold cutoff for DNA contamination (260/280) at 2.0. cDNA was synthesized (SuperScript III; Invitrogen) using 250 ng RNA and random hexamers according to the manufacturer’s instructions. qPCR assays were performed using aRotor-Gene Q (Qiagen) with SYBR-Green chemistry (GoTaq qPCR Master Mix; Promega) and previously published gene-specific primers: \textit{PAX6} forward: 5'-TCTTTGCTTTGGAAATCCG-3' and reverse: 5'-CTGCCCCGTTACAATTCCTTAG-3'; glyceraldehyde 3-phosphate dehydrogenase (\textit{GAPDH})\textsuperscript{22-25}}
forward: 5'-GAAGGTAAGGTGGTCGAGTC-3' and reverse: 5'-GAAGATGTGATGGAGTATTGTTT-3'. Primer specificity was tested using gel electrophoresis (to verify single band and amplicon size), DNA sequencing, and melting profile. A no-reverse transcription control was included in each run for detection of potential PCR contamination. Normalized PAX6 expression relative to GAPDH was calculated using the \( 2^{-\Delta\Delta Ct} \) method.\(^{26}\)

**Statistical analysis.** Data are presented as mean of three independent experiments (\( n = 3 \)) + standard deviation (SD). Significance (\( P < 0.05 \)) was assessed using a paired \( t \)-test (RT-qPCR) and ANOVA Tukey’s post-hoc analysis (luciferase assay) in R (version 3.0.2).\(^{27}\)

**Results and Discussion**

The human PAX6 3′-UTR contains two functional miR-7 target sites. There are seven verified human PAX6 transcripts in the NCBI database, which result from alternative splicing and alternative initiation of transcription. However, it is noteworthy that they all share identical 3′-UTRs accounting for approximately 75% of the total mRNA sequence, which allows for the suggestion that PAX6 expression is possibly regulated by miRNAs. Using TargetScan software,\(^{9}\) we identified three miR-7 target sites: one of which (m8#1) has previously been shown to regulate PAX6 expression in mouse\(^{9}\) and two additional miR-7 target sites (m8#2 and A1#3) were predicted when poorly conserved target sites were considered (Fig. 1A). Two of the three predicted miR-7 target sites within the 3′-UTR contained 7mer-m8 seed matches (m8#1 and m8#2), whereas the third target site contained a lower hierarchy 7mer-A1 seed match (A1#3)\(^{4}\) (Fig. 1B). Noticeably, the A1#3 target site has a mismatch at position 8 in the miR-7 sequence (Fig. 1B), which has been shown to be essential for functional miR-7-target binding.\(^{28}\)

To examine the functional significance of the three predicted human miR-7 target sites within the PAX6 3′-UTR, we generated firefly luciferase reporter constructs containing each of these individual sites, as well as Mut constructs of each. We then co-transfected HEK293 cells with the firefly and Renilla (transfection control) luciferase constructs and either hsa-miR-7 or miR-NC (a negative control) precursor miRNAs to assess target specificity. To confirm the reliability of our assay, we first measured luciferase activity of a construct containing a perfect miR-7 target site (5′-CAACAAAAT-CACCTAGCTTCCA-3′), which resulted in a 99% reduction in luciferase activity (Renilla normalized) compared to cells transfected with miR-NC precursors (Fig. 1C). Assessment of cells transfected with PAX6 3′-UTR target site firefly luciferase reporter plasmids revealed that two of the three miR-7 target sites (m8#1 and m8#2) were functionally active, each yielding a significant reduction in luciferase activity of approximately 45% with miR-7 relative to their Mut target.

**Figure 1.** The human PAX6 3′-UTR contains two specific, functional miR-7 target sites. (A) Prediction of miRNA-7 target sites within the human PAX6 3′-UTR. Black line (top) illustrates the length of the PAX6 3′-UTR (k = kilobase), and asterisks illustrate predicted miR-7 target sites (m8#1, m8#2, and A1#3). (B) Alignment of predicted human PAX6 miR-7 target sites (top) to miR-7 (bottom). The seed target region (GUCUCC) is in bold, and the seed matches, target sites, and positions are given. (C) Luciferase assays using firefly reporter constructs with predicted (WT: wild type and Mut) miR-7 7mer target sites (m8#1, m8#2, and A1#3) and a perfect miR-7 target site (PT) as a positive control. The firefly luciferase reporters were co-transfected into HEK293 cells with a Renilla luciferase reporter as a transfection control and either miR-7 or miR-NC precursors. Relative luciferase expression (firefly normalized to Renilla) values of hsa-miR-7 were normalized to miR-NC transfected controls, and is given as mean + SD. The relative luciferase activity (firefly normalized to Renilla) of the positive control was calculated as miR-7 relative to miR-NC and is given as mean + SD, *\( P < 0.05 \).
site reporters (Fig. 1C). Both of these active sites contained 7mer-m8-predicted miR-7 target sites, whereas the third site (7mer-A1#3) did not show any regulation by miR-7. Our study therefore confirms previous findings, showing that Watson-Crick base pairing to nucleotide position 8 is essential for functional miR-7-target binding.28

Taken together, these data indicate that the PAX6 3′-UTR contains two 7 mer-m8 miR-7 seed sites. A third predicted 7 mer-A1 miR-7 target site that did not comply with Watson-Crick pairing at nucleotide 8 failed to show functional activity in luciferase reporter assays.

**PAX6 protein expression is regulated by miR-7 in human cells.** To assess whether miR-7 regulates PAX6 protein expression in human cells, we transiently transfected HeLa, a human cervical cancer cell line, with miR-7 precursor molecules and measured PAX6 levels by Western blotting. Compared with a negative miRNA precursor molecule (miR-NC), miR-7 reduced expression of PAX6 in HeLa cells (Fig. 2A). To determine whether miR-7 reduced PAX6 protein levels through interfering with the translational pathway or mediating mRNA decay, we assessed endogenous PAX6 mRNA levels by RT-qPCR; however, we saw no significant difference in *PAX6* mRNA expression between HeLa cells transfected with hsa-miR-7 or miR-NC miRNA precursor molecules (Fig. 2B).

Taken together, these data indicate that miR-7 regulates PAX6 protein levels in human cells, but has no significant effect on mRNA levels, which suggests that miR-7 interferes with the translational pathway rather than mediating *PAX6* mRNA decay.

**Diversification of PAX6 3′-UTR miR-7 target sites across species.** Recent experiments in mice have demonstrated that miR-7 directly represses the expression of *PAX6* through a single miR-7 target site in the mouse *PAX6* 3′-UTR.8,9 Given our identification of a second functional miR-7 target site (7mer-m8) in human *PAX6* 3′-UTR compared to mouse, we examined the evolutionary conservation of *PAX6* 3′-UTRs and their miR-7 target sites across species, and found that the length of *PAX6* 3′-UTRs varied considerably and that this length seemed to be associated with the number of predicted miR-7 target sites (Fig. 3A). For example, in primates, human (*Homo sapiens*) and rhesus monkey (*Macaca mulatta*), *PAX6* has relatively long 3′-UTRs (accounting for more than 70% of the total mRNA sequences), and we demonstrated the existence of two functional 7mer-m8 miR-7 target sites within these regions. In comparison, the 3′-UTRs of pig (*Sus scrofa*), rodents (*Mus musculus* and *Rattus norvegicus*), and fish (*Danio rerio*) account for between 30 and 39% of total *PAX6* mRNA length and contain only one predicted miR-7 target site (Fig. 3A). In other species such as chicken (*Gallus gallus*) and fruit fly (*Drosophila melanogaster*), where the 3′-UTR accounts for less than 20% of the total *PAX6* mRNA sequence, no miR-7 target sites were predicted (Fig. 3A). Notably, in zebrafish, there are two duplicated *PAX6* gene variants, *PAX6a* and *PAX6b*, with distinct 3′-UTR lengths, accounting for 34%–39% of the total mRNA lengths, respectively (Fig. 3A). *PAX6a* contains a single predicted miR-7 target site, whereas no site was predicted in the shorter 3′-UTR of the *PAX6b* variant, suggesting that perhaps only *PAX6a* is post-transcriptionally regulated by miR-7. Also, the fruit fly has multiple *PAX6* gene loci, from which six different *PAX6* 3′-UTRs are transcribed; none have a predicted miR-7 target site in the 3′-UTR despite one transcript having a 3′-UTR that accounts for more than 45% of the total mRNA sequence (Fig. 3A), suggesting that miR-7 might not regulate *PAX6* expression levels in fruit flies. These results are in agreement with previous work that suggested the expansion of 3′-UTR sequences increases with organism complexity throughout evolution.29

In summary, given our finding that miR-7 can regulate *PAX6* 3′-UTR, sequence alignment revealed that 20 of 23 nucleotides were conserved and that all predicted miR-7 target sites shared identical 7mer-m8 seed regions (Fig. 3B). Thus, the first functional human 7mer-m8 *PAX6* miR-7 target site (more 5′-located; m8#1 in Figure 1) appears to be conserved, whereas the second functional human 7mer-m8 miR-7 target site (more 3′-located; m8#2 in Figure 1) does not. The identification of a miR-7 target site positioned outside the conserved region suggests that this site may have resulted from the expansion of the *PAX6* 3′-UTR. The appearance of multiple functional miR-7 binding sites within the human *PAX6* 3′-UTR suggests an added level of complexity by allowing the combinatorial regulation of *PAX6* expression by miR-7.7

In summary, given our finding that miR-7 can regulate *PAX6* expression via two miR-7 target sites in a human cell line, future experiments are needed to examine the physiological importance of this regulatory system, in particular, examining whether there is a combinatorial effect between the two functional human miR-7 target sites (m8#1 and m8#2).
or if a dysfunctional miR-7/PAX6 regulatory system promotes tumorigenesis, as both factors are highly associated with cancer.\textsuperscript{30–34}

**Conclusions**

In conclusion, we provide the first demonstration that miR-7 regulates the expression of PAX6 protein in human cells, and show that this regulation occurs via two target sites within the \textit{PAX6} 3′-UTR: the first site is highly conserved across species, whereas the second functional miR-7 site is conserved only in primates. This finding leads to the intriguing possibility that the expanded 3′-UTR found in human \textit{PAX6} may allow for a tighter control of \textit{PAX6} expression by miR-7 than that already documented in mouse.

**Author Contributions**

MN, RBW, KMG, SAD, and MGT conceived and designed the experiments. MN, RBW, KMG, and MGT analyzed the...
data. MN wrote the first draft of the manuscript. MN, RBW, KMG, SAD, and MGT contributed to the writing of the manuscript. MN, RBW, KMG, SAD, and MGT agreed with manuscript results and conclusions. MN, RBW, KMG, SAD, and MGT jointly developed the structure and arguments for the paper. MN, RBW, KMG, SAD, and MGT made critical revisions and approved the final version. All authors reviewed and approved the final manuscript.

DISCLOSURES AND ETHICS
As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

REFERENCES
1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
3. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115(7):797–9.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.
5. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27(1):91–105.
6. Kertesz M, Lovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278–84.
7. Vo NK, Cambronne XA, Goodman RH. MicroRNA pathways in neural development and plasticity. Curr Opin Neurobiol. 2010;20(4):457–65.
8. Kredo-Russo S, Mandelbaum AD, Ness A, et al. Pancreas-enriched microRNA refines endocrine cell differentiation. Development. 2012;139(16):3021–31.
9. de Chevigny A, Coet N, Follert P, et al. mir-7a regulation of Pax6 controls spatial origin of forebrain dopaminergic neurons. Nat Neurosci. 2012;15(9):1120–6.
10. Arora A, McKay GJ, Simpson DA. Prediction and verification of miRNA expression in human and rat retinas. Invest Ophthalmol Vis Sci. 2007;48(9):3962–7.
11. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009;284(9):5731–41.
12. Jiang L, Liu X, Chen Z, et al. MicroRNA-7 targets IGFR1 (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J. 2010;432(1):199–205.
13. Du R, Gutierrez-Perez I, Ferrer-Marco D, Dominguez M. Dampening the signals transduced through Hedgehog via microRNA miR-7 facilitates notch-induced tumourigenesis. PLoS Biol. 2013;11(5):1–16.
14. Wang Y, Liu J, Liu C, Naji A, Stoffers DA. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic beta-cells. Diabetes. 2013;62(3):887–95.
15. Ericson J, Rashbass P, Schedl A, et al. Pax6 controls progenitor cell identity and neuronal fate in response to graded Shh signaling. Cell. 1997;90(3):369–80.
16. Götz M, Stoykova A, Gruss P. Pax6 controls radial glia differentiation in the cerebral cortex. Neuron. 1998;21(5):1031–44.
17. Stoykova A, Gruss P. Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci. 1994;14(3 pt 2):1395–412.
18. Daly JM, Doly JM, Beveridge DJ, et al. The 3’-untranslated region of p21 WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. J Biol Chem. 2003;278(5):2977–46.
19. Zhang X, Huang CT, Chen J, et al. Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell. 2010;7(1):90–100.
20. Li XJ, Zhang X, Johnson MA, Wang ZB, Lavaute T, Zhang SC. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. Development. 2009;136(23):4055–63.
21. Belinsky GS, Stiris CL, Rich MT, et al. Dopamine receptors in human embryonic stem cell neurodifferentiation. Stem Cells Dev. 2013;22(10):1522–40.
22. Lin MC, Liu YC, Tam MF, Lu YJ, Hsieh YT, Lin LY. PTEN interacts with metal-responsive transcription factor 1 and stimulates its transcriptional activity. Biochem J. 2012;441(1):367–77.
23. Guo H, Wu X, Yu FS, Zhao J. Toll-like receptor 2 mediates the induction of IL-10 in corneal fibroblasts in response to Fusarium soli. Immunol Cell Biol. 2008;86(3):271–6.
24. Lukasiak S, Schiller C, Oehlschlager P, et al. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene. 2004;23(46):6068–74.
25. Li J, Chen Y, Qin X, et al. Mir-181 downregulates miRNA processing in HeLa cells by targeting RMDNS A and decreasing Exportin-5 stability. Nucleic Acids Res. 2014;42(1):458–74.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.
27. R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing [Computer Program]. Version 3.0.2. Vienna, Austria: R Foundation for Statistical Computing; 2013.
28. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 2005;3(3):e85.
29. Mazumder B, Seshadri V, Fox PL. Translational control by the 3’-UTR: the ends specify the means. Trends Biochem Sci. 2003;28(2):91–8.
30. Shyr CR, Tsai MY, Yeh S, et al. Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate. 2010;70(2):190–9.
31. Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R, Lang D. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MIT tyrosine kinase receptor gene. J Biol Chem. 2009;284(40):27524–32.
32. Zong X, Yang H, Yu Y, et al. Possible role of Pax-6 in promoting breast cancer cell proliferation and tumorigenesis. BMB Rep. 2011;44(9):595–600.
33. Zhao X, Yue W, Zhang L, et al. Downregulation of PAX6 by shRNA inhibits proliferation and cell cycle progression of human non-small cell lung cancer cell lines. PLoS ONE. 2014;9(1):e85738.
34. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res. 2013;73(18):5609–12.

Needhansen et al
**Supplementary Data**

**Table 1.** PAX6 3′ untranslated regions.

| SPECIES            | VARIANTS | ACCESION NUMBERS | 3′ UTR (START-STOP) |
|--------------------|----------|------------------|---------------------|
| Homo Sapiens       | N/A      | NM_001127612.1   | 1739–6883           |
| Macaca mulatta     | N/A      | NM_001266257.1   | 1711–5908           |
| Sus scrofa         | N/A      | NM_001244172.1   | 1728–2643           |
| Mus musculus       | N/A      | NM_001244198.1   | 1597–2619           |
| Rattus norvegicus  | N/A      | NM_013001.2      | 1430–2191           |
| Gallus gallus      | N/A      | NM_205066.1      | 1641–1961           |
| Xenopus tropicalis | N/A      | NM_001006762.1   | 1651–2361           |
| Danio rerio        | PAX6a    | NM_131304.1      | 1845–2809           |
|                    | PAX6b    | NM_131641.1      | 1575–1733           |
| Drosophila Melanogaster |       | NM_166789.2  | 2621–2851           |

**Notes:** List of PAX6 GenBank accession numbers, N/A = “not applicable.” Nucleotide position numbers for the 5′end (start) and 3′end (stop) of the 3′-UTRs are listed.

**Table 2.** Oligonucleotides used for generating firefly luciferase constructs.

| TARGET SITES | OLIGONUCLEOTIDES (5′–3′) |
|--------------|--------------------------|
| m8#1         | WT                       | AGCTTTCTGGATTTCTAGGGAAGACAATACTTACATTGGACATATAAAAAAATT |
|              | AS                       | CTAAGGATTTGGTGCAAAATGTGAAGTATTTGCTTTCCCTAGAATAATCTGAAAGAGACCTTATCCTGATTGACCATATAAAAAAATT |
| m8#2         | WT                       | AGCTAGTGAAGTTTGGCAAGGAAGACTTATCCTGATTGACCATATAAAAAAATT |
|              | AS                       | CTAAGGATTTGGTGCAAAATGTGAAGTATTTGCTTTCCCTAGAATAATCTGAAAGAGACCTTATCCTGATTGACCATATAAAAAAATT |
| A1#3         | WT                       | AGCTAAATAATCTCAACAGCGATTTGGTGGAATAAAACATCTCGAATTTCAACACACCTGACATACCCCA |
|              | AS                       | CTAAGGATTTGGTGCAAAATGTGAAGTATTTGCTTTCCCTAGAATAATCTGAAAGAGACCTTATCCTGATTGACCATATAAAAAAATT |

**Notes:** List of sense (SE) and antisense (AS) oligonucleotides used for generating firefly luciferase constructs containing WT and Mut miR-7 7mer target sites (m8#1, m8#2, and A1#3). Italic, bold, and underlined nucleotides represent restriction recognition-, miR-7 target- and mut sites, respectively.